ACTO Named a Luminary in Everest Group’s 2026 Agentic AI in Life Sciences Commercial Innovation Watch
ACTO has been named a Luminary in Everest Group’s Innovation Watch: Agentic AI in Life Sciences Commercial 2026, an assessment of 22 agentic AI product and platform providers serving Life Sciences commercial organizations.
The report explores how agentic AI is being applied across product launch, pricing and market access, medical affairs, marketing effectiveness, sales force engagement, and patient support—along with the technologies and capabilities shaping adoption across the industry.
What Is Everest Group’s Agentic AI in Life Sciences Commercial Innovation Watch?
Life Sciences commercial organizations are exploring agentic AI to improve productivity, customer engagement, and decision-making across increasingly complex workflows.
At the same time, teams continue to navigate fragmented data, manual processes, evolving payer dynamics, compliance requirements, and growing expectations for more personalized engagement.
Everest Group examines how capabilities such as reasoning, workflow orchestration, and contextual intelligence can help address these challenges through prebuilt and customizable agents and low-code/no-code agent-builder platforms.
This 87-page report includes:
- A comparative assessment of 22 agentic AI product and platform providers for Life Sciences commercial organizations
An overview of provider capabilities across Life Sciences commercial use cases - A look at key commercial business challenges and the role of agentic AI in improving productivity, engagement, and decision-making
- Insight into commercial use cases and adoption priorities with strong near-term potential
Explore the Future of Agentic AI in Life Sciences Commercial
Complete the form to receive Everest Group’s Innovation Watch: Agentic AI in Life Sciences Commercial 2026 and begin exploring emerging use cases, compare leading providers, and learn why ACTO was named a Luminary.
“ACTO differentiates through its role-based approach to agentic AI in life sciences commercial, combining domain-specific SuperAgents with cross-platform orchestration and life sciences-focused governance. Its growing partner ecosystem and early customer deployments further support enterprise adoption, positioning ACTO as Luminary in Everest Group’s Innovation Watch: Agentic AI in Life Sciences Commercial 2026.”
– Rohit Khuttan, Practice Director, Everest Group